Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc has a strong positive outlook due to the advanced clinical data showing that its candidate RLY-2608 demonstrates superior efficacy and tolerability compared to capivasertib, which may lead to swift market acceptance. Additionally, RLY-2608 is anticipated to increase the overall penetration of PI3Ka inhibitors and potentially expand the market opportunity, which is currently valued at approximately $700 million with ongoing growth. The company's innovative Dynamo platform, focusing on precision medicine for oncology and genetic diseases, underlines its commitment to addressing previously challenging drug targets, further enhancing its growth prospects.

Bears say

The negative outlook on Relay Therapeutics Inc. stems from significant concerns regarding the projected median progression-free survival (mPFS) for its drug candidates, which is expected to decline by approximately 80%, from 24 months to just 5 months, raising alarm regarding the efficacy of these therapies. Additionally, the commercial launch of its product inavolisib has been disappointing due to safety liabilities linked to the drug’s inhibition mechanism, particularly affecting metabolically unfit patients, further undermining market expectations for a first-line product. Furthermore, declining sales in related therapeutics, such as Piqray, due to heightened competition in the market, illustrate further pressures on the company's financial prospects and overall market position.

RLAY has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Strong Buy based on their latest research and market trends.

According to 7 analysts, RLAY has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.